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Background: We previously reported the value of our operative procedure for Budd-Chiari syndrome (BCS) that
comprised reconstruction of the occluded or severely stenosed inferior vena cava (IVC) using an autologous pericardium
patch and reopening as many occluded hepatic veins as possible. Here, we present the long-term durability and efficacy
of the autologous pericardium patch for reconstruction of the IVC in BCS.
Methods:We retrospectively analyzed a series of 53 consecutive patients (mean age, 48.4 12.8 years; range, 24-76 years;
34 men) who underwent surgical treatment for BCS at our institution from 1979 to 2008. Patency of the IVC and
hepatic veins was examined by venography at discharge. Patients attended an outpatient clinic every 1 or 2 months for
follow-up. The reconstructed IVC was evaluated by enhanced computed tomography every 1 or 2 years.
Results: Two in-hospital (operative mortality, 3.7%) and 15 late deaths occurred. During a mean follow-up of 7.6  6.5
years (range, 0.08-24.1 years), the reconstructed IVC became totally obstructed in three patients, of whom two
underwent reoperation, and severely stenosed in two patients, who required percutaneous transvenous balloon veno-
plasty (PTV). The 5- and 10-year patency rates without reoperation or PTV for the reconstructed IVC were 90.5% and
84.3%, respectively. The cumulative 5- and 10-year survival rates were 89.8% and 70.7%, respectively.
Conclusion: The autologous pericardium patch is effective and durable for reconstructing a diseased IVC in BCS. (J Vasc
Surg 2009;50:590-3.)Budd-Chiari syndrome (BCS) is defined as chronic,
progressive, and congestive liver dysfunction resulting in
liver cirrhosis and hepatic failure due to hepatic inferior
vena cava (IVC) obstruction concomitant with ostial ob-
struction of the hepatic vein. We previously described our
corrective procedure for BCS that consists of reconstruc-
tion of the occluded IVC using autologous pericardium
patch and reopening as many occluded hepatic veins as
possible.1-3
Malignant involvement of the IVC or superior vena
cava (SVC) is sometimes surgically treated using autolo-
gous pericardium, which is considered good material for
patch reconstruction after partial resection of the IVC or
SVC.4-7 We previously demonstrated that autologous peri-
cardium is more effective than bovine or horse pericardium
and expanded polytetrafluoroethylene (ePTFE) for recon-
struction of the IVC in dogs.8 However, the long-term
durability and efficacy of this autologous pericardium after
patch reconstruction of the IVC in patients with BCS is
unclear. To clarify the effectiveness and long-term durabil-
ity of the autologous pericardium for patch reconstruction
of the IVC, we retrospectively reviewed patients with BCS
who had undergone our surgical corrective procedure.
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590PATIENTS AND METHODS
We enrolled 53 consecutive patients (34 men) who had
undergone this corrective procedure for BCS at Ryukyu
University Hospital between December 1979 and January
2008. The patients were a mean age of 48.4  12.8 years
(range, 24-76 years). Major symptoms or signs were lower
extremity edema in 11, abdominal distension in 10, hepatic
encephalopathy in 6, hepatomegaly in 5, superficial collat-
eral veins on the abdomen in 5, varicose vein or pigmenta-
tion of the leg in 5, gastrointestinal bleeding in 4, and
abdominal pain in 2. All patients had ascites at the opera-
tion. Three patients had associated Behçet’s disease, 6 had
a protein C deficiency, 5 had protein S deficiency, and 1 had
antiphospholipid antibody syndrome. Esophageal varices
were confirmed in 46 patients (87%), of which six (11.3%)
had a history of hepatic encephalopathy.
The mean pressure gradient between the right atrium
(RA) and IVC was 12.0  3.4 mm Hg (range, 8-21 mm
Hg). The 15-minute indocyanine green clearance test
(ICG 15’) was 30.4%  16.4% (range, 5.3%-68%). Preop-
erative venography showed that the obstructed or stenosed
lesion of the IVC was 3.0  2.6 cm (range, 0-12 cm) in
length. Three patients had undergone previous catheter
intervention to the IVC stenosis. Our surgical indication
for BCS is an IVC obstruction or severe stenosis resulting in
elevation of the pressure gradient between RA and IVC,
with or without a hepatic vein with ostial obstruction,
which is thought to be able to be reopened by our proce-
dure, simultaneously.
The patients were placed in the left lateral position
under unilateral ventilation, and the lateral site of the
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the diaphragm and right sixth intercostals by a thoracot-
omy. Harvested fresh autologous pericardium was im-
mersed in saline and used to reconstruct the occluded or
severely stenosed IVC (Fig 1). We concomitantly reopened
as many occluded hepatic veins as possible under a partial
cardiopulmonary bypass (CPB) through the right femoral
artery and vein cannulation. A thickened caval wall that
occluded the ostia of the hepatic veins was partially resected
with some liver parenchyma to reopen and dilate the he-
patic venous outflow. The concept of lateral patch augmen-
tation and resection of liver parenchyma is to widen and
deepen the occluded or severely stenosed hepatic IVC and
normalize hepatic circulation from the portal vein to the
RA through the hepatic veins.
All patients received continuous intravenous heparin
sulfate at a dose of 100 U/kg/day within 24 to 48 hours
postoperatively, followed by lifelong warfarin therapy at
doses required to maintain the international normalized
ratio between 1.5 and 2.5.
All surviving patients underwent venography and the
ICG 15’ test at discharge and were followed up every 1 or
2 months as outpatients. The reconstructed IVC was eval-
uated by enhanced computed tomography (CT) scanning
every 1 or 2 years. During the follow-up period, 129 CT
images of the surviving patients, with an average of 4.3
images per patient (range, 1-14 images) were reviewed.
When restenosis or occlusion of the hepatic IVC was indi-
cated on scans, the patients underwent venography. The
last imaging study that confirmed graft patency served as
the end point for graft patency calculations.
Statistical analysis was performed with Statview 5.0
software (SAS Institute, Cary, NC). All data were expressed
as mean  SD. The survival rate and the patency rate
without reoperation and transvenous balloon venoplasty
(PTV) for the reconstructed IVC were estimated using the
Kaplan-Meier product limit method. For comparison be-
tween two groups, significance was determined by the t
Fig 1. Reconstructed retrohepatic inferior vena cava (IVC) with
fresh autologous pericardium patch. RA, right atrium.test. A value of P  .01 was considered significant.RESULTS
The duration was 298.5  83.4 minutes (range, 180-
567 minutes) for the procedure and 30.5  15.5 minutes
(range, 13-71 minutes) for CPB. The harvested pericar-
dium was 72 (range, 40-120)  34 (range, 24-86) mm.
Two patients died in the hospital at postoperative day 15
for an operative mortality of 3.7%. One patient died of
severe liver failure and the other died of ventricular fibrilla-
tion from cardiac amyloidosis. The postoperative hospital
length of stay was 49  22 days (range, 15-124 days).
Complications developed in 11 patients, consisting of pleu-
ral effusion in 5, postoperative bleeding in 2, wound infec-
tion in 2, renal dysfunction in 1, and acute hepatitis in 1.
Symptoms were acceptably reduced in all survivors, with no
evidence of hepatic failure.
All survivors underwent venography at discharge,
which revealed the absence of occlusion and severe stenosis
in the reconstructed IVC. The mean pressure gradient
between the RA and IVC was significantly decreased from
12.0  3.4 (range, 8-21) to 4.0  3.0 (range, 0.0-12.0)
mm Hg (P  .001). The ICG 15’ was also significantly
decreased from 30.4%  16.4% (range, 5.3%-68%) to
19.7% 14.6% (range, 5.5%-56.6%; P .001). The serum
bilirubin and platelet count were significantly recovered
from 1.62  0.7 (range 0.6-3.4) to 1.19  0.67 (range,
0.3-4.0) mg/dL (P  .001) and from 11.5  7.5 (range,
2.0-48.4)  104/mm3 to 16.3  7.8 (range, 3.6-35.0) 
104/mm3 (P  .001). The esophageal varices disappeared
in 11 of 46 patients (23.9%).
No graft infections developed during themean follow-up
period of 7.6  6.5 years (range, 0.08-24.1 years). Total
obstruction of the reconstructed IVC occurred in three
patients at 5, 6, and 7 years, respectively, after the initial
surgery. Two of three patients with total obstruction,
whose symptoms of lower extremity edema and esophageal
varices deteriorated despite medical treatment, underwent
a repeat procedure. One patient underwent repeated IVC
reconstruction using a ring-reinforced ePTFE graft, and
another underwent a Senning-type RA-liver anastomosis.
Four presented with severe stenosis of the reconstructed
IVC that was treated using PTV. The 5- and 10-year
patency rates without reoperation or PTV for the recon-
structed IVC were 90.5% and 84.3%, respectively (Fig 2).
The remaining patients did well with considerable improve-
ment of symptoms that were documented before surgery
and no progression of the liver dysfunction during the
follow-up period. Hepatocellular carcinoma developed in
13 patients (24.5%), and they underwent partial hepatic
resection 5.3  5.4 years (range, 0-17.6 years) after the
BCS surgery, including a one-stage operation in three
patients.
There were 15 late deaths caused by hepatocellular
carcinoma in 2 patients, pneumonia in 2, respiratory failure
in 1, arrhythmia in 1, suicide in 1, liver failure in 1, and an
unknown cause in 7. The cumulative 5- and 10- year
survival rates were 89.8% and 70.7%, respectively (Fig 3).
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These results suggest that autologous pericardium can
serve as an effective and durable patch for IVC reconstruc-
tion in BCS. Because of its geometric and functional advan-
tages, antibacterial and anticoagulant potential, long-term
durability without calcification, and its cost, the autologous
pericardium is considered an excellent material for recon-
structive heart surgery9-15 and for treating tumors with
vascular involvement and thrombosis.4-7 It has been ap-
plied in many reconstructive procedures such as right ven-
tricular outflow tract repair of tetralogy of Fallot, aortic
arch reconstruction in hypoplastic left heart syndrome,
heart valve repair, and aortic root repair in aortic valve
endocarditis.9-15
Our previous immunohistologic findings8 also support
the use of autologous pericardium for IVC reconstruction
in terms of the quality of the neointima of grafts after patch
reconstruction of the IVC in dogs. Moreover, the pericar-
dium can be easily harvested through a thoracoabdominal
incision approached through the retrohepatic IVC and RA
in patients with BCS.
The autologous pericardium has some limitations,
however. The size of the pericardium available for harvest
Fig 2. Cumulative patency rates without reoperation or percuta-
neous transvenous balloon venoplasty. Patency rates are 90.5% at 5
years and 84.3% at 10 years.
Fig 3. Cumulative survival rates were 89.8% at 5 years and 70.7%
at 10 years.using our approach might be insufficient for IVC repair inpatients who have already undergone cardiac surgery or our
procedure for BCS, so an alternative material is required for
such patients. The ePTFE graft that has mostly been used
for IVC replacement or patch reconstruction in patients
with tumors or thrombus involving the IVC is considered a
good material for treating patients with BCS from the
viewpoints of size-matched IVC, resistance to compres-
sion, and high patency rates, regardless of anticoagulant
therapy.16-19
One of two patients with an obstructed IVC required
repeated patch augmentation with an external supported
ePTFE graft 6 years after the first operation; however,
severe edema of both feet developed 16 years after the
repeat operation. Venography revealed severe stenosis of
the proximal site of the graft, and the pressure gradient
across this stenosis site had increased from 0 (at the first
operation) to 8 mmHg. PTV did not resolve his symptoms
or reduce the pressure gradient due to sclerotic change at
the stenosis site of previous ePTFE graft. Three other
patients with severe stenosis of the autologous pericardium
underwent successful PTV. These findings suggested that
the anastomotic site of the ePTFE graft might undergo
long-term sclerotic changes.
In the setting of anticoagulation therapy, inherited and
acquired hypercoagulable states along with a variety of
other causes can be identified in about 75% of patients with
BCS, indicating that several etiologic factors are involved in
25% of these patients.20 Therefore, our patients were ad-
ministered indefinite postoperative warfarin therapy. In
fact, six (11%) of our patients with BCS had inherited and
acquired hypercoagulable states. Moreover, the two in-
hospital deaths occurred in patients who had hypercoagu-
lable states and presented fulminant liver failure before
surgery.
Transjugular intrahepatic portosystemic shunt (TIPS)
is thought to be feasible and effective in patients with
fulminant or acute BCS, and is also useful as a bridge to
liver transplantation. The long-term success of the TIPS is
limited, however, particularly in patients with liver cirrho-
sis.21,22 In our series, 32 patients (60.3%) had histologic
liver cirrhosis, and their cumulative survival rates were
93.3% at 5 years and 78.2 % at 10 years. So, TIPS should be
considered as a bridge to definitive surgery in case of
fulminant or acute liver failure of BCS with liver cirrhosis.
CONCLUSIONS
Fresh autologous pericardium is an effective and dura-
ble patch for reconstruction of the IVC in BCS. This
technique has a good long-term outcome.We consider that
long-term anticoagulant therapy with warfarin is necessary
for such hypercoagulable states.
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